Trial Profile
Phase I Study of the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 With Blocking of Autocrine Loops VEGFR1/2/3
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs LYN 00101 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Lynkcell
- 10 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.
- 10 Mar 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Jun 2020.
- 10 Mar 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.